TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed prostate cancer (mixed histology is acceptable, with the exception of the small cell pure phenotype, which is excluded)~* Received a taxane-based chemotherapy for the treatment of metastatic prostate cancer with evidence of disease progression on or after treatment, or discontinued from a taxane-based chemotherapy due to an adverse event~* Received a second-generation or later androgen receptor (AR)-targeted therapy (for example, abiraterone acetate plus prednisone, enzalutamide, apalutamide) for the treatment of metastatic prostate cancer with evidence of disease progression or non-metastatic castration-resistant prostate cancer with evidence of subsequent metastasis~* Biomarker-positive by at least one of the following criteria: (a) Biallelic deoxyribonucleic acid (DNA)-repair anomaly based on a sponsor validated blood or tissue assay; (b) Germline pathogenic Breast Cancer gene (BRCA) 1 or BRCA2 by any test (somatic local results must be confirmed as positive by the sponsor-validated assay before dosing)~* Progression of metastatic prostate cancer in the setting of castrate levels of testosterone or history of bilateral orchiectomy at study entry~Exclusion Criteria:~* Prior treatment with a poly (adenosine diphosphate \[ADP\] ribose) polymerase (PARP) inhibitor~* Prior platinum-based chemotherapy for the treatment of prostate cancer~* Known history or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)~* Symptomatic or impending cord compression~* Symptomatic brain metastases

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Niraparib (Type: EXPERIMENTAL): Participants will receive 300 milligram (mg) niraparib (3 capsules\*100 mg) orally once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.~* Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis~Exclusion Criteria:~* Subject had previously received systemic or biologic anti-IL-12 therapy~* Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVB or PUVA phototherapy~* Subject is taking or requires oral or injectable corticosteroids~* Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study~* Female subject who is pregnant or breast-feeding or considering becoming pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Anti IL-12 monoclonal antibody/ABT-874, up to 12 weeks, 200 mg every week for 12 weeks
- 2 (Type: ACTIVE_COMPARATOR): Anti IL-12 monoclonal antibody/ABT-874, 200 mg QOW for 12 weeks
- 3 (Type: ACTIVE_COMPARATOR): Anti IL-12 monoclonal antibody/ABT-874, 100 mg QOW in 12 weeks
- 4 (Type: ACTIVE_COMPARATOR): Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 4 doses in 12 weeks
- 5 (Type: ACTIVE_COMPARATOR): Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 1 dose in 12 weeks
- 6 (Type: PLACEBO_COMPARATOR): placebo, 12 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mesalazine and/or Lactobacillus Casei in the Diverticular Disease of the Colon

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of diverticular disease diagnosed for the first time or established by previous colonoscopy~* symptomatic episode of uncomplicated diverticular disease no more than 4 weeks prior to study entry~* patients who have given their free and informed consent.~Exclusion Criteria:~* acute diverticulitis (both complicated and uncomplicated)~* diverticular colitis~* active or recent peptic ulcer~* chronic renal insufficiency~* allergy to salicylates~* patients with intended or ascertained pregnancy, lactation~* women of childbearing age not using contraceptives~* lactulose-lactitol use in the two weeks before the enrolment and during the study~* presence of diverticulitis complications (fistulas, abscesses, and/or stenoses)~* use of probiotic preparations either prescribed or over-the counter within two weeks prior to study entry~* inability to give a valid informed consent or to properly follow the protocol~* patients with active malignancy of any type, or history of a malignancy (patients with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years before study enrolment were also acceptable)~* recent history or suspicion of alcohol abuse or drug addiction~* any severe pathology that can interfere with the treatment or the clinical or instrumental tests of the trial~* use of NSAIDS for one week before and throughout the study period (only paracetamol was permitted).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mesalazine (Type: ACTIVE_COMPARATOR): Active mesalazine 800 mg, 2 tablets/day for 10 days/month plus Lactobacillus casei placebo, 1 sachet/day for 10 days/month.
- Lactobacillus casei (Type: ACTIVE_COMPARATOR): Active Lactobacillus casei, 1 sachet/day for 10 days/month plus mesalazine 800 mg placebo, 2 tablets/day for 10 days/month.
- Mesalazine plus Lactobacillus casei (Type: ACTIVE_COMPARATOR): Active mesalazine 800 mg, 2 tablets/day plus active Lactobacillus casi, 1 sachet/day for 10 days/month.
- Placebo (Type: PLACEBO_COMPARATOR): Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma（NewEC Study）

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically documented untreated SCC or adenocarcinoma of the oesophagus or gastro-oesophageal junction.~* Patients clinically staged as stage I-III (T1-3, N0-1 and M0) as assessed by a contrast-enhanced multislice computed tomography (CT) scan, positron emission tomography, or endoscopic ultrasonography.~* Patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.~Exclusion Criteria:~* Patients had received any previous treatment for oesophageal cancer.~* Patients who were unsuitable for surgery because of comorbidities.~* Patients had evidence of distant metastatic disease by history and physical examination.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant chemoradiotherapy (Type: None): Patients who had chemoradiotherapy before surgery.
- Neoadjuvant chemotherapy (Type: None): Patients who had chemotherapy before surgery.
- Surgery alone (Type: None): Patients who only had oesophagectomy. Various surgical oesophagectomy methods were used, such as Ivor Lewis, transthoracic, three-hole, transhiatal, and left transthoracic. The appropriate surgical approach for each patient was chosen according to the tumour location, size, and depth.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Stage 0-III breast cancer who are scheduled to receive endocrine therapy with tamoxifen or an aromatase inhibitor~* All prior surgery and chemotherapy should be complete~* Age 18 and above and postmenopausal~Exclusion Criteria:~* Major rheumatologic disorders~* Concomitant sex hormone containing drugs or Leutinizing Hormone Releasing Hormone agonist therapy~* For those subjects initiating treatment with an aromatase inhibitor, prior tamoxifen within 4 weeks of enrollment~* For those subjects initiating treatment with tamoxifen, prior aromatase inhibitor within 4 weeks of enrollment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AI therapy (Type: None): Subjects who started treatment with any of the three aromatase inhibitor (AI) medications
- Tamoxifen (Type: None): Subjects who started treatment with tamoxifen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomised Controlled Trial of Electroconvulsive Therapy (ECT) in Relapse Prevention of Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. MINI-PLUS verified major depressive episode (unipolar or bipolar).~2. ECT within the last 3 weeks.~3. Either Remission defined as MADRS \< 10 or~4. Response defined as MADRS \< 15 combined with patient assessed CGI-I of at least much improved~Exclusion Criteria:~1. Schizophrenia or Schizoaffective disorder~2. Addiction or Dependence~3. Kidney disease that contraindicates lithium treatment~4. Vascular or heart disease that contraindicates venlafaxine treatment~5. Uncontrolled Epilepsia~6. Age less that 18~7. Pregnancy or Lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ECT+pharmacotherapy (Type: EXPERIMENTAL): Unilateral brief pulse ECT weekly for 6 weeks thereafter every 2 weeks; Venlafaxine target dose 300mg/day; Lithium target dose 0,5-0,8 mmol/L.
- pharmacotherapy (Type: ACTIVE_COMPARATOR): Venlafaxine target dose 300mg/day; Lithium 0,5-0,8 mmol/L.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with melanoma based on International Classification of Disease 9th and 10th Revisions (ICD-9: 172.x; ICD-10: C43x, D03x) and ≥2 visits on different days in the Flatiron database on or after January 1, 2011.~* Clinically confirmed diagnosis of melanoma with pathologic stages III or IV at initial diagnosis or earlier stage disease with a first locoregional or distant recurrence on or after January 1, 2011.~* Age ≥18 years at the time of advanced melanoma diagnosis.~* Evidence of ≥1 BRAF positive test result at any time based on laboratory or genetic analysis results.~Exclusion Criteria:~-• Patients with prior BRAF- or MEK-inhibitor therapy~• Patients with ECOG performance status ≥ 2 (at the time of randomization for patients from COLUMBUS, during the baseline period for patients in Flatiron EHR)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Encorafenib + binimetinib (Type: None): Encorafenib 450 mg once a day (QD) Binimetinib 45 mg twice a day (BID)
- Vemurafenib + Cobimetinib (Type: None): Vemurafenib 960 mg twice a day (BID) for 28 days of 28 day cycle Cobimetinib 60 mg once a day (QD) for 21 days of 28 day cycle
- Dabrafenib + trametinib (Type: None): Dabrafenib 150 mg twice a day (BID) Trametinib 2 mg once a day (QD)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Must have been taking a stable dose of basal or premixed insulin for 8 weeks or longer prior to screening~* If taking metformin, must have been taking the same daily dose for 8 weeks or longer prior to screening~* Insulin type should be intermediate- or long-acting (basal) or premixed (premixed formulation may include short- or rapid-acting insulin as 1 component).~* Inadequate glycemic control (A1C of 7.5% to 11.0%, inclusive)~* Body mass index of 45 kg/m² or lower~* Fasting C-peptide level of 0.8 ng/mL or higher~Exclusion Criteria:~* Symptoms of poorly controlled diabetes, including but not limited to marked polyuria and polydipsia with greater than 10% weight loss during the last 3 months prior to screening or other signs and symptoms~* History of diabetic ketoacidosis or hyperosmolar nonketotic coma~* Women of childbearing potential unable or unwilling to use acceptable birth control~* Women who are pregnant or breastfeeding~* Active liver disease~* Anemia~* Chronic or repeated intermittent corticosteroid treatment (participants receiving stable doses of replacement corticosteroid (except dexamethasone) therapy may be enrolled)~* Use of short- or rapid-acting insulin~* Significant cardiovascular history defined as: myocardial infarction, coronary angioplasty or bypass graft, valvular disease or repair, unstable angina pectoris, transient ischemic attack, or cerebrovascular accident~* Congestive heart failure~* Unstable or rapidly progressing renal disease~* History of alcohol or drug abuse within the previous year~* History of hemoglobinopathies~* Unstable major psychiatric disorders~* Immunocompromised status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin, 5 mg + insulin (Type: EXPERIMENTAL): Saxagliptin, 5 mg, plus insulin, administered to participants with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
- Placebo + insulin (Type: PLACEBO_COMPARATOR): Placebo administered to participants with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnostic and Statistical Manual - Fourth Edition (DSM-IV) diagnosis of schizoaffective disorder~* A total Positive and Negative Symptoms of Schizophrenia (PANSS) score of \>= 60~* A score of \>= 16 on Young Mania Rating Scale (YMRS) or a score of \>= 16 on the Hamilton Depression Rating Scale (HAM-D 21)~Exclusion Criteria:~* A primary active mental illness diagnosis other than schizoaffective disorder~* Patients with first episode psychosis~* Active substance dependence within previous 6 months~* Treatment with clozapine within 6 months of randomization~* A history of treatment resistance, defined by failure to respond to 2 adequate trials of antipsychotic medication~* Pregnancy, breast-feeding, or planning to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 002 (Type: EXPERIMENTAL): Paliperidone ER 12mg/day paliperidone er for 6 weeks
- 001 (Type: EXPERIMENTAL): Paliperidone ER 6mg/day paliperidone er for 6 weeks
- 003 (Type: PLACEBO_COMPARATOR): Placebo Placebo for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a clinical diagnosis of either open angle glaucoma or ocular hypertension.~* Currently on beta-blocker monotherapy (for \>30 days) and would benefit, in the opinion of the investigator, from further intraocular pressure (lOP) reduction.~* Have a mean baseline lOP of \>18 mmHg and \<32 mmHg in at least one eye.~* Must be able to understand and sign an Informed Consent form.~* Other protocol-specified inclusion criteria may apply.~Exclusion Criteria:~* Use of medication excluded by the protocol.~* Diseases, illnesses, infections, or ocular abnormalities excluded by the protocol.~* Ocular surgeries or procedures excluded by the protocol.~* Best-corrected visual acuity (BCVA) score worse than 55 ETDRS letters (equivalent to 20/80 Snellen, 0.60 logMAR or 0.25 decimal).~* Hypersensitivity to prostaglandin analogues or any component of the study medications in the opinion of the investigator.~* Women of childbearing potential if pregnant, test positive for pregnancy at Screening visit, breastfeeding, or not in agreement to use adequate birth control methods to prevent pregnancy throughout the study.~* Other protocol-specified exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DuoTrav (Type: EXPERIMENTAL): Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 8 weeks.
- Beta-blocker (Type: ACTIVE_COMPARATOR): Participant's current beta-blocker monotherapy, 1 drop instilled in the study eye twice daily (morning and evening) for 4 weeks, followed by travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 4 additional weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of type 2 diabetes mellitus, according to the American Diabetes Association diagnostic criteria, ≥ 3 months at time of randomization~* HbA1c in the range of 6.5 - 9.5% (inclusive) at screening~* Treatment with diet and exercise alone or a stable dose of metformin, or sulfonylurea, or metformin plus a sulfonylurea for at least 4 weeks prior to randomization~* Further criteria as defined in the clinical trial protocol~Exclusion Criteria:~* Symptoms of hyperglycemia (i.e. polyuria and polydypsia)~* History of significant weight gain or loss (+/-5%) during the 4 weeks before randomization~* Fasting C-peptide level \< 400 pmol/L at screening~* Change in the medicamentous treatment of elevated blood pressure, diabetes mellitus or dyslipidemia within 4 weeks prior to the randomization~* Use of any weight loss medication (over the counter prescription) or initiation of a prescribed weight management or exercise program within 4 weeks before randomization~* Current systemic anti-inflammatory therapy other than aspirin ≤ 100 mg/day or immunosuppressive treatment, in particular oral corticosteroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete